The FDA cited data from the Neurodevelopmental Effects of Antiepileptic Drugs study, published in March 2013, which found that at age 6, children whose mothers had taken valproate
products while pregnant had lower IQs, compared with those whose mothers took other antiepileptic drugs.
When the researchers ran the numbers, they found that prenatal valproate
exposure was connected with an absolute risk for autism of 4.
More than one in 10 (12%; 6 out of 50) children whose mums had taken valproate
alone during their pregnancy had a neurodevelopmental problem, as did one in seven (15%; 3 out of 20) of those whose mums had taken valproate
with other drugs.
is, for some people, the only drug that can control their epilepsy, so the findings on dosage and the beneficial effects of folic acid could be useful.
, lamotrigine, and insulin-mediated risk in women with epilepsy.
In a multivariate analysis of the intent-to-treat sample of 310 children, IQ was lower among children exposed in utero to valproate
compared with children of mothers who took other antiepileptic drugs (AEDs) during pregnancy.
is extensively conjugated to glucuronic acid, and more than half of an ingested dose is excreted in the urine as the glucuronide, along with smaller amounts of hydroxylated valproate
metabolites and their glucuronide conjugates.
If manic symptoms are a prominent feature, consider using valproate
300 mg 2 x daily, increasing to 600 mg 2 x daily; use lower doses and monitor liver function tests if liver impairment is present.
Verification of the fetal valproate
Professor of Clinical Neuropsychology at the university, Gus Baker, said "We looked at how exposure to sodium valproate
and other anti-epilepsy drugs (AED) in the womb affected children's everyday life - in particular their IQ, memory and language abilities from one to six years of age.
children had IQ scores six to nine points lower by age 3, said the study's lead author, Dr Kimford Meador of Emory University.
The efficacy and safety of ABILIFY, used in combination with lithium or valproate
for the treatment of patients with Bipolar I Disorder, were investigated during a 6-week multicentre, double-blind, randomized, placebo-controlled study involving 348 patients, followed by a 46-week open-label extension phase.